Rezolute — First Quarter Fiscal 2027 Earnings Summary

Rezolute, Inc. reported a net loss of $18.5 million for the first quarter of fiscal 2027, with cash and investments totaling $90.0 million as of September 30, 2026. The company's Phase 3 upLIFT study for tumor hyperinsulinism has completed enrollment, with top-line results expected by mid-December 2026. For congenital hyperinsulinism, the FDA has recommended filing a Biologics License Application following a pre-BLA meeting, despite the primary endpoint not being met in the sunRIZE study. Rezolute plans to submit a BLA for its investigational therapy, ersodetug, in 2027 for one or both indications, targeting a combined market opportunity of $5 billion.